Login to Your Account



ODAC Focusing on Cardiac Toxicities with Carfilzomib

By Karen Pihl-Carey
Staff Writer

Tuesday, June 19, 2012
Two days ahead of an FDA advisory committee meeting focused on Onyx Pharmaceuticals Inc.'s new drug application for Kyprolis (carfilzomib), briefing documents highlighted the agency's concern over severe cardiac toxicities and the possibility that the second-generation proteasome inhibitor may not offer an advantage over existing multiple myeloma therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription